PinealonvsSS-31

Pinealon is a short tripeptide (Glu-Asp-Arg) belonging to the Khavinson family of peptide bioregulators — small peptides hypothesised to regulate gene expression in tissue-specific ways by binding directly to DNA promoter regions. Pinealon is the brain- and pineal-gland-targeted member of this family, designed to penetrate cells and the nuclear membrane to interact with promoter sequences of genes involved in neuronal function and circadian regulation.

Proposed mechanisms include modulation of melatonin synthesis pathways (via effects on pineal gland function), upregulation of antioxidant defence enzymes in neurons, and protection against oxidative stress from age-related accumulation of reactive oxygen species. Russian preclinical studies have reported pinealon-induced increases in expression of genes involved in serotonin and melatonin metabolism, neurotrophic factor signalling, and antioxidant capacity, alongside protective effects against neurotoxin-induced neuronal damage in animal models.

The extremely short plasma half-life (around 30 minutes) is a feature shared with all Khavinson tripeptides — the proposed model is that the peptides act as transient signalling molecules that trigger longer-lasting changes in gene expression, with effects persisting well beyond plasma clearance. This model would explain the use of pulse-dosing protocols (10-30 day courses repeated periodically) rather than continuous administration. Importantly, almost all published efficacy data comes from Russian research groups associated with the original Khavinson laboratory, and the bioregulator framework has not been independently validated in Western clinical settings. Mechanistic claims should be treated as preliminary, and clinical use remains largely anecdotal outside Russia.

SS-31 (elamipretide, D-Arg-Dmt-Lys-Phe-NH2) is a cell-permeable, mitochondria-targeted tetrapeptide with an alternating aromatic-cationic motif that drives its remarkable 1,000-fold concentration within mitochondria. This accumulation is driven by the highly negative mitochondrial membrane potential (-180 mV), which electrostatically attracts the cationic peptide, and by its lipophilic aromatic residues which partition into the inner mitochondrial membrane.

Once concentrated in the inner mitochondrial membrane, SS-31 selectively binds to cardiolipin — a unique dimeric phospholipid found almost exclusively in this membrane. Cardiolipin plays an essential structural role: it anchors cytochrome c to the inner membrane surface, optimizing electron transfer between Complex III and Complex IV of the electron transport chain (ETC). With aging and disease, cardiolipin undergoes peroxidation by reactive oxygen species (ROS), which disrupts its interaction with cytochrome c. Loosened cytochrome c transfers electrons less efficiently, increasing electron leak to molecular oxygen and generating more ROS — creating a vicious cycle of mitochondrial decline.

SS-31 breaks this cycle by stabilizing the cardiolipin-cytochrome c interaction, restoring optimal electron transfer efficiency and reducing ROS generation at the source. It also protects cardiolipin from peroxidation by ROS scavenging through its dimethyltyrosine (Dmt) residue. The downstream effects are profound: restored mitochondrial membrane potential, improved ATP production, reduced oxidative damage to mitochondrial DNA and proteins, and prevention of the mitochondrial permeability transition pore (mPTP) opening that triggers apoptosis. In aged tissues, where mitochondrial dysfunction is a hallmark of cellular decline, SS-31 effectively rejuvenates mitochondrial function toward a younger phenotype. Clinical studies have shown improvements in skeletal muscle energetics, cardiac function, and exercise tolerance in elderly subjects and patients with mitochondrial myopathy.